Clinical trials: Hyperparathyroidism; Secondary, Renal
Chronic Kidney Disease, Secondary Hyperparathyroidism
Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease
Active forms of vitamin D and its analogs are used to treat elevated parathyroid hormone levels and bone disease in chronic kidney disease (CKD).
- Trial name
- NCT01426724
- Testing
- Contrast Enhanced Ultrasonography
- Where
- United States
- Sponsor
- University of Virginia
Renal Osteodystrophy
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD
The proposed 6 month pilot and feasibility randomized trial will evaluate LMMS as an anabolic stimulus to bone in 30 adults on maintenance hemodialysis.
- Trial name
- NCT00364234
- Testing
- Low magnitude mechanical stimuli
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Secondary Hyperparathyroidism, Disorder Related to Renal Transplantation
Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation
The purpose of the study is to evaluate the long term vascular morbidity and mortality in kidney transplant recipients based on one year post transplant levels of intact parathyroid hormone.
- Trial name
- SHPT-RT (NCT01741064)
- Volunteers
- 257 people
- Sponsor
- Skane University Hospital
Secondary Hyperparathyroidism
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
The purpose of this trial is to determine the safety and tolerability of ascending single and multiple oral doses of LEO 27847 in secondary hyperparathyroidism patients.
- Trial name
- NCT01167309
- Testing
- LEO 27847
- Where
- 2 sites in Germany, Poland
- Volunteers
- 72 people
- Sponsor
- LEO Pharma
Chronic Kidney Disease
Paricalcitol Injection Phase II Trial
The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal…
- Trial name
- NCT00646932
- Testing
- paricalcitol
- Where
- 10 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Abbott
Chronic Kidney Disease 5D, Secondary Hyperparathyroidism Due to Renal Causes
A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation
1. Study content: This is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin D insufficiency or deficiency in patients with CKD5d; to…
- Conditions
- Chronic Kidney Disease 5D, Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Deficiency
- Trial name
- NCT05549154
- Testing
- High-dose vitamin D2 softgels, low-dose vitamin D2 softgels
- Where
- China
- Volunteers
- 372 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic-kidney Disease Stage 5D on Stable Hemodialysis
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105
The purpose of the study is to evaluate the safety, tolerability, and PK following single and multiple ascending dose administration of VS-105 in healthy subjects and patients with chronic kidney disease stage 5D (CKD-5D) on…
- Trial name
- NCT03043482
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Vidasym, Inc.
Secondary Hyperparathyroidism, End Stage Kidney Disease
Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2
This study is to evaluate the efficacy and safety of PLS240 in patients with hemodialysis-dependent end stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT). The study consists of two phases.
- Trial name
- PATH-2 (NCT05836220)
- Testing
- PLS240, Open-Label Extension PLS240
- Where
- 68 sites in United States, Bulgaria and 4 more
- Volunteers
- 412 people
- Sponsor
- Pathalys Pharma
Chronic Kidney Disease, Secondary Hyperparathyroidism
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
- Trial name
- IMPACT SHPT (NCT00977080)
- Testing
- Paricalcitol, Cinacalcet
- Where
- 83 sites in United States, Czechia and 10 more
- Volunteers
- 272 people
- Sponsor
- Abbott
Secondary Hyperparathyroidism, Hypercalcemia
Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
Secondary hyperparathyroidism can persist following successful renal transplantation and can cause high blood calcium, kidney dysfunction or failure and excessive bone loss among other problems.
- Trial name
- NCT00415584
- Testing
- Cinacalcet HCl
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Montefiore Medical Center
Adynamic Bone Disease, Chronic Kidney Diseases
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for…
- Conditions
- Adynamic Bone Disease, Chronic Kidney Diseases, Cardiac Disease, Chronic Kidney Disease-Mineral and Bone Disorder
- Trial name
- NCT04522622
- Testing
- Teriparatide, DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT, Bone biopsy
- Where
- 4 sites in Denmark
- Volunteers
- 48 people
- Sponsor
- Ditte Hansen
Chronic Kidney Disease
Different Effects of Non-calcium Phosphate Binders on Serum Calcium
Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and calcium, and hormones regulating mineral-bone…
- Trial name
- NCT03451019
- Testing
- Sevelamer Hydrochloride, Lanthanum Carbonate
- Where
- Poland
- Volunteers
- 34 people
- Sponsor
- Medical University of Lodz
Secondary Hyperparathyroidism, Chronic Kidney Disease
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.
- Trial name
- NCT02341417
- Testing
- Cinacalcet
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 28 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism, End-Stage Renal Disease
Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice
The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT).
- Trial name
- NCT01134315
- Testing
- Paricalcitol, Calcitriol
- Where
- 18 sites in United States
- Volunteers
- 61 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy
The Effect of Etelcalcetide on CKD-MBD
The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and blood-vessels healthier.
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
- Trial name
- Parsabiv-MBD (NCT03960437)
- Testing
- Etelcalcetide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Thomas Nickolas, MD MS
Osteoporosis, Chronic Kidney Disease Mineral and Bone Disorder
Osteoporosis & Renal Disease: Research in Primary Health Care Services
Osteoporosis, a silent and multifactorial systemic skeletal disorder, severely compromises bone strength and significantly increases the risk of fragility fractures.
- Trial name
- NCT07848490
- Testing
- Fracture risk assessment tool (FRAX), Dual-Energy X-ray Absorptiometry (DXA)
- Where
- Portugal
- Volunteers
- 622 people
- Sponsor
- Universidade do Porto
Chronic Kidney Disease, Secondary Hyperparathyroidism
Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis
The primary objective was to evaluate the efficacy of cinacalcet for reducing the plasma intact parathyroid hormone (iPTH) level by ≥ 30%.
- Trial name
- NCT02138838
- Testing
- Cinacalcet HCl, Standard of Care
- Where
- 60 sites in United States, Belgium and 14 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Chronic Kidney Disease, Hyperparathyroidism, Secondary
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and tolerability of CTAP101 will also be evaluated
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
- Trial name
- NCT01651000
- Testing
- CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- OPKO IP Holdings II, Inc.
Chronic Kidney Disease, End Stage Renal Disease
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification
- Trial name
- NCT00379899
- Testing
- cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Chronic Kidney Diseases, Hyperparathyroidism, Secondary
Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation
While the duration of renal transplant function has increased over the last decade kidney transplanted patients (KTP) still exhibit a fracture risk 4 times higher than in the general population.
- Trial name
- TRANSBONE (NCT02523209)
- Testing
- HR-pQCT, DEXA
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne